Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Invested Capital (2019 - 2023)

Historic Return on Invested Capital for Coherus Oncology (CHRS) over the last 4 years, with Q4 2023 value amounting to 1.27%.

  • Coherus Oncology's Return on Invested Capital changed N/A to 1.27% in Q4 2023 from the same period last year, while for Dec 2023 it was 1.27%, marking a year-over-year change of. This contributed to the annual value of 1.24% for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q4 2023, Coherus Oncology's Return on Invested Capital is 1.27%.
  • In the past 5 years, Coherus Oncology's Return on Invested Capital registered a high of 1.27% during Q4 2023, and its lowest value of 0.56% during Q3 2021.
  • Over the past 4 years, Coherus Oncology's median Return on Invested Capital value was 0.29% (recorded in 2019), while the average stood at 0.4%.
  • In the last 5 years, Coherus Oncology's Return on Invested Capital soared by 9500bps in 2020 and then plummeted by -16200bps in 2021.
  • Coherus Oncology's Return on Invested Capital (Quarter) stood at 0.18% in 2019, then soared by 123bps to 0.4% in 2020, then crashed by -241bps to 0.56% in 2021, then soared by 327bps to 1.27% in 2023.
  • Its last three reported values are 1.27% in Q4 2023, 1.22% for Q3 2023, and 0.56% during Q3 2021.